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Abstract: Aim: This study aimed at evaluating the prevalence of high anticardiolipin antibody and lupus anticoagulant 
levels in women with histories of at least two miscarriages. 
Methods: The presence of high anticardiolipin antibody and lupus anticoagulant levels were evaluated in 52 patients with 
ages between 17 and 41 (mean 26.7 years old) who had histories of repeated miscarriages. 
Results: High anticardiolipin antibody levels were identified in 55.77% and lupus anticoagulant levels in 2% of the 
individuals. 
Conclusion: In conclusion, women who suffer from repeated miscarriages present with a high prevalence of 
anticardiolipin antibodies. Further studies on this issue are crucial as these antibodies are associated with 
hypercoagulability and thus increased the risk of thromboembolic events. 
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INTRODUCTION 
  Antiphospholipid syndrome (APS), in relation to 
pregnancy, is characterized by the presence of 
antiphospholipid autoantibodies in association with repeated 
fetal loss and complications such as pre-eclampsia, retarded 
fetal growth or placental insufficiency [1, 2]. This syndrome 
constitutes a heterogeneous group of circulating antibodies 
against anionic phospholipids with the most important ones 
being Anticardiolipin Antibodies (ACA), a positive Venereal 
Disease Research Laboratory test (VDRL) and lupus 
anticoagulants [2, 3]. False-positive VDRL results do not 
constitute diagnostic criteria for the syndrome due to the low 
sensitivity and specificity of the test. However, high levels in 
pregnant women should serve as a warning of the presence 
of antiphospholipid antibodies [4]. 
  In pregnant women, an APS rate from 0.2% to 2% is 
similar to the frequency in the general population [5], 
however, this syndrome is responsible for about 10% of the 
cases of repeated miscarriages [6, 7]. 
  Several publications have associated APS with retarded 
intrauterine growth [8, 9] and others with pre-eclampsia [5, 
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  Antibodies of this syndrome can inhibit placental 
anticoagulant protein by binding to phospholipids, thereby 
leading to thrombosis [13], and also by influencing the 
production of gonadotropin [14]. The 2 glycoproteins act as 
a cofactor in the binding of antiphospholipid antibodies to 
anionic phospholipids, thus functioning as a natural 
anticoagulant and therefore any interference in this system 
may result in thrombosis [15]. In an animal model, 
spontaneous miscarriages were observed with passive 
transfer of purified anticardiolipin IgG [1, 16]. 
  Treatment using heparin, aspirin or intravenous 
immunoglobulins reduces the rate of fetal loss. Risk of pre-
eclampsia and placental insufficiency occurs in around 50% 
of non-treated patients and the success rate of prophylactic 
treatment using heparin and aspirin is approximately 70% 
[1]. The reduction of these symptoms with the normalization 
of the levels of ACA is associated to an improvement in the 
survival rate of fetuses during pregnancy [17]. 
  This current study aimed at evaluating the prevalence of 
high ACA and lupus anticoagulant levels in women who had 
suffered two or more miscarriages. 
METHODS 
  In a retrospective study, 52 consecutive pregnant women 
who had suffered from two or more miscarriages were 
evaluated in a teaching hospital in São José do Rio Preto, 
São Paulo, Brazil, in a period from April 1988 to November 
2003. Their ages ranged from 17 to 41 years old with a mean 
of 26.7 years. Inclusion criteria were a history of multiple 
miscarriages (2 or more) and positive results for ACA tests. Anticardiolipin and Repeated Miscarriages  The Open Rheumatology Journal, 2010, Volume 4   29 
No patient had a history of rheumatologic disease before 
pregnancy. Patients who suffered not more than one 
miscarriage were excluded from the study. Evaluation of the 
ACA was achieved by Enzyme-Linked Immunosorbent 
Assay (ELISA – Quanta Lite
TM  ACA IgG/IgM INOVA 
Diagnostics). Lupus anticoagulant was investigated using the 
activated partial thromboplastin time (aPTT) prolonged by 
the presence of an inhibitor. For statistical analysis, simple 
percentages and the Fisher exact test were utilized with an 
alpha error of 5% (p-value < 0.05) were considered 
acceptable. 
  The study was approved by the Ethics Committee of the 
Medical School in São Jose do Rio Preto, Brazil (FAMERP). 
RESULTS 
  Abnormally high ACA levels were detected in 55.77% of 
the women and lupus anticoagulant in 2%. 
  High IgM ACA levels were found in 41.1% of the cases, 
high IgG ACA in 17.6% and high levels for both IgM and 
IgG ACA were identified in 38.2% of the cases. There was 
no significant difference between the number of patients 
with high IgG and IgM immunoglobulin levels when 
analyzed using the Fisher exact test (p-value < 0.09). 
DISCUSSION 
  High ACA levels are harmful to the normal evolution of 
gestation and can affect both mother and child. Diagnosis 
and prophylactic treatment can improve the outcome of the 
pregnancy [1, 18]. The current study detected an abnormally 
high rate of pregnant women who had suffered repeated 
miscarriages with high serum levels of these antibodies. The 
prevalence of lupus anticoagulant (2%) was lower than the 
rate of ACA (55.7%). Thus, it is important to highlight this 
high prevalence as venous thromboembolism has been 
identified as one of the commonest causes of maternal death 
[19, 20]. This should be seen as a warning about the 
necessity to investigate hypercoagulability states during 
pregnancy particularly in respect to antiphospholipid 
antibodies. We should continue to be aware of maternal 
complications other than miscarriages. Some published 
investigations did not identify any association between 
antiphospholipid antibodies and repeated miscarriages [21, 
22], but other studies did [23, 24]. This demonstrates the 
need for further studies using larger number of individual 
and standardization of the investigational methods. Gestation 
and puerperium are associated with thromboembolism [25, 
26], thus an association of risk factors in maternal 
thromboembolism is implicated. 
  In the evolution of these patients it is observed that the 
ACA levels may vary, and even may become negative. In 
this group, three patients had a history of thrombotic events; 
two deep venous thrombosis and one myocardial infarction. 
Thrombotic events are associated with the syndrome and 
physicians should be watchful about this possibility. 
  The prevalence of patients with high levels of these 
antibodies in the current study is within the range cited by 
other studies, as publications have reported a prevalence of 
these antibodies in from 15 to 59.1% of cases [26-28]. This 
variation is due to the different methods employed to 
measure the antibodies and so there is a true necessity of 
standardization. 
  Another warning is related to the possibility of false-
positive VDRL results and their interpretation that can cause 
psychological instability within the family [29]. 
CONCLUSION 
  In conclusion, individuals suffering from repeated 
miscarriages are frequently present with antiphospholipid 
antibody syndrome. These data indicate the necessity of a 
systemic investigation of these antibodies in pregnant 
women. 
COMPETING INTERESTS 
  The authors declare that they have no competing interests 
(political, personal, religious, ideological, academic, 
intellectual, commercial or any other) in relation to this 
manuscript. 
REFERENCES 
[1]  Heilmann L, von Tempelhoff GF, Pollow K. Antiphospholipid 
syndrome in obstetrics. Clin Appl Thromb Hemost 2003; 9(2): 143-
50. 
[2]  Wendell AW, Ghavari AE, Koike T, et al. International consensus 
statement on preliminary classification for definitive 
antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11. 
[3]  de Godoy JM, de Godoy MF, Braile DM, Torres CA. Prevalence of 
anticardiolipin antibodies in peripheral arterial thrombosis. 
Angiology 2000; 51(6): 473-7. 
[4]  Gutierrez M, Scopeletis E, Cabrera G, et al. Anticardiolipin 
Antibodies Syndrome: pathological considerations. Rev Bras 
Reumatol 1993; 33: 101-6. 
[5]  Branch DW, Dudlwy DJ, Scott IR, Silver JM. Antiphospholipid 
antibodies and fetal loss. N Engl J Med 1992; 326: 951-2. 
[6]  Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin 
and lupus anticoagulant in systemic lupus erythematosus (SLE) and 
in non-SLE disorders; prevalence and clinical. Ann Intern Med 
1990; 112: 682-98. 
[7]  Cowchock S. The role of antiphospholipid antibodies in obstetric 
medicine. Curr Obstet Med 1991; 1: 229-47. 
[8]  Nilsson IM, Asted B, Hedner V, Berezin D. Intrauterine death and 
circulating anticoagulant (antithromboplastin). Acta Med 1975; 
197: 153-9. 
[9]  Lockshin M D, Druzin M L, Goei S, et al. Antibody to cardiolipin 
as a predictor of fetal distress or death in pregnant patients with 
systemic Lupus Erythematosus. N Eng J Med 1985; 18: 152-6. 
[10]  Silver RM, Porter TF, van Levween I, Jeng G, Scott JR, Branch 
DW. Anticardiolipin antibodies: clinical consequences of “low 
titer”. Obstet Gynecol 1996; 87: 494-500. 
[11]  Out HJ, Bruinse HW, Christianes GC, et al. A prospective 
controlled multicenter study on the obstetric risks of pregnant 
women with antiphospholipid antibodies. Am J Obstet Gynecol 
1992; 167: 26-32. 
[12]  Stuart RA, Kormann LH, Mc Hugh NJ. A prospective study of 
pregnancy outcome in women screened at a routine antenatal clinic 
for anticardiolipin antibodies. Br J Obstet Gynaecol 1993; 100: 
599-600. 
[13]  Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin 
MD. Phospholipid binding of antiphospholipid antibodies and 
placental anticoagulant protein. J Clin Immunol 1992; 12: 27-35. 
[14]  Di Simone N, Meroni PL, de Papa N, et al. Antiphospholipid 
antibodies affect trophoblast gonadotropin secretion and 
invasiveness by binding directly and through adhered beta2-
glycoprotein I. Arthritis Rheum 2000; 43(1): 140-50. 
[15]  C Bu, C Zhang, Z Li, Gao L, Xie Z, Cai G. Autoantibodies to 
plasminogen and tissue plasminogen activator in women with 
recurrent pregnancy loss. Clin Exp Immunol 2007; 149(1): 31-9. 
[16]  Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld 
Y. Induction of primary antiphospholipid syndrome in mice by 30   The Open Rheumatology Journal, 2010, Volume 4  Spegiorin et al. 
immunization with a human monoclonal anticardiolipin antibody. J 
Clin Invest 1992; 89: 1558-63. 
[17]  Salazar-Paramo M, Jara LJ, Ramos A, Barile L, Machado G, 
García-De La Torre I. Longitudinal study of antinuclear and 
anticardiolipin antibodies in pregnant women with systemic lupus 
erythematosus and antiphospholipid syndrome. Rheumatol Int 
2002; 22(4): 142-7.  
[18]  Vials JM. A literature review on the antiphospholipid syndrome 
and the effect on childbearing. Midwifery 2001; 17(2): 142-9. 
[19]  Department of Health, Welsh Office, Scottish Home and Health 
Department of Health and Social Services, Northern Ireland. 
Confidential Enquiries into Maternal Deaths in United Kingdom, 
1991-1993. London: HMSO, 1996. 
[20]  The ministry of Welfare, Children and Families Bureau Maternal 
and Child Heath Division Maternal and Child Heath Statistic of 
Japan Tokyo: The Ministry of Welfore, 1999, pp. 76-8. 
[21]  Branch DW, Silver R, Pierangeli S, Van Leeuwen I, Harris N. 
Antiphospholipid antibodies other than lupus anticoagulant and 
Anticardiolipin antibodies in women with recurrent pregnancy loss, 
fertile controls, and Antiphospholipid syndrome. Obstet Gynecol 
1997; 89: 549-55. 
[22]  Simpson JL, Carson SA, Chesney C, et al. Lack of association 
between antiphospholipid antibodies and first-trimester sponta-
neous abortion: prospective study of pregnancies detected within 
21 days of conception. Fertil Steril 1998; 69(5): 814-20. 
[23]  Ogishima D, Matsumoto T, Nakamura Y, Yoshida K, Kuwabara Y. 
Placental pathology in systemic lupus erythematosus with 
antiphospholipid antibodies. Pathol Int 2000; 50(3): 224-9. 
[24]  Mello G, Parretti E, Martini E, et al. Usefulness of screening for 
congenital or acquired hemostatic abnormalities in women with 
previous complicated pregnancies. Haemostasis 1999; 29(4): 197-
203. 
[25]  Martinelli I, de Stefano V, Taioli E, Paciaroni K, Rossi E, 
Mannucci PM. Inherited thrombophilias and first venous 
thromboembolism during pregnancy and puerperium. Thromb 
Haemost 2002; 87: 791-5. 
[26]  Godoy JMP, Spegiorin LCJF, Dallaqua J, Carvalho CFC, Costa IL. 
Gestation in patients with high levels of anticardiolipin antibodies, 
a history of deep venous thrombosis and miscarriages. Arch Med 
Sci 2006; 23: 205-7. 
[27]  Galli M, Barbui T. Antiphospholipid antibodies and pregnancy. 
Best Pract Res Clin Haematol 2003; 16(2): 211-25. 
[28]  Spegiorin LCJF, Godoy JMP, Oliani AH. Evaluation of 
prophylaxis using low doses of heparin associated with aspirin in 
pregnancy with multiple miscarriages and high antiphospholipid 
antibody levels. Arch Med Sci 2007; 3: 43-45. 
[29]  Godoy JMP, Spergiorin LC, Gallaqua J, de Carvalho CF, Costa IL. 
Repeated miscarriages in a patient with a high level of 
anticardiolipin antibodies and myocardial infarction. Prague Med 
Rep 2006; 107(4): 443-6. 
 
 
Received: March 24, 2010  Revised: April 18, 2010  Accepted: June 11, 2010 
 
© Spegiorin et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 
3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 
 
 